TAGRISSO Patient Savings Program*
*Patients must meet all eligibility requirements to be enrolled in the program.
Helping patients access the care they need
The AstraZeneca Access 360™ program provides personal support to help streamline access and reimbursement for TAGRISSO. Access 360 provides:
Accessing quality and timely molecular testing
TAGRISSO is available for order from the following specialty providers
TAGRISSO is available for purchase from these authorized specialty distributors
TAGRISSO is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.
Please see complete Prescribing Information including Patient Information.
You may report side effects related to AstraZeneca products by clicking here.